These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

996 related items for PubMed ID: 27542267

  • 1. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
    Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M, Oguri T, Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu H, Bandoh S, Himeji D, Ohira T, Shimokawa M, Nakanishi Y, Nakagawa K, Nishio K.
    Oncotarget; 2016 Sep 06; 7(36):58492-58499. PubMed ID: 27542267
    [Abstract] [Full Text] [Related]

  • 2. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y.
    Oncologist; 2016 Feb 06; 21(2):156-64. PubMed ID: 26768482
    [Abstract] [Full Text] [Related]

  • 3. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
    Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O'Connell A, Feeney N, Mach SL, Jänne PA, Oxnard GR.
    JAMA Oncol; 2016 Aug 01; 2(8):1014-22. PubMed ID: 27055085
    [Abstract] [Full Text] [Related]

  • 4. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
    Ko R, Kenmotsu H, Serizawa M, Koh Y, Wakuda K, Ono A, Taira T, Naito T, Murakami H, Isaka M, Endo M, Nakajima T, Ohde Y, Yamamoto N, Takahashi K, Takahashi T.
    BMC Cancer; 2016 Nov 08; 16(1):864. PubMed ID: 27821131
    [Abstract] [Full Text] [Related]

  • 5. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H, Azuma K, Sakai K, Kawahara A, Yamada K, Tokito T, Okamoto I, Nishio K, Hoshino T.
    Oncotarget; 2015 Oct 13; 6(31):30850-8. PubMed ID: 26334838
    [Abstract] [Full Text] [Related]

  • 6. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
    Wang W, Song Z, Zhang Y.
    Cancer Med; 2017 Jan 13; 6(1):154-162. PubMed ID: 28000387
    [Abstract] [Full Text] [Related]

  • 7. [Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor].
    Cao ZY, Wu W, Hou LK, Zhang W, Gao CX, Wu CY, Zhang LP.
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec 08; 47(12):910-914. PubMed ID: 30522170
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y, Xiong L, Xie F, Zheng X, Li Y, Zhu L, Sun J.
    Cancer Med; 2021 Jul 08; 10(14):4697-4709. PubMed ID: 34173341
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
    Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S, Fujita S, Kaji R, Imai Y, Monden K, Matsumoto T, Nagata K, Otsuka K, Tachikawa R, Tomii K, Kunimasa K, Iwasaku M, Nishiyama A, Ishida T, Nishimura Y.
    Cancer; 2013 Dec 15; 119(24):4325-32. PubMed ID: 24105277
    [Abstract] [Full Text] [Related]

  • 14. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
    Takahama T, Azuma K, Shimokawa M, Takeda M, Ishii H, Kato T, Saito H, Daga H, Tsuboguchi Y, Okamoto I, Otsubo K, Akamatsu H, Teraoka S, Takahashi T, Ono A, Ohira T, Yokoyama T, Sakai K, Yamamoto N, Nishio K, Nakagawa K.
    Cancer; 2020 Jan 01; 126(9):1940-1948. PubMed ID: 32022929
    [Abstract] [Full Text] [Related]

  • 15. Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.
    Wei B, Zhao C, Li J, Zhao J, Ren P, Yang K, Yan C, Sun R, Ma J, Guo Y.
    Mol Oncol; 2019 May 01; 13(5):1226-1234. PubMed ID: 30927306
    [Abstract] [Full Text] [Related]

  • 16. A Rapid and Sensitive Method for Detection of the T790M Mutation of EGFR in Plasma DNA.
    Kimura H, Nishikawa S, Koba H, Yoneda T, Sone T, Kasahara K.
    Adv Exp Med Biol; 2016 May 01; 924():171-174. PubMed ID: 27753039
    [Abstract] [Full Text] [Related]

  • 17. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
    Lee JY, Qing X, Xiumin W, Yali B, Chi S, Bak SH, Lee HY, Sun JM, Lee SH, Ahn JS, Cho EK, Kim DW, Kim HR, Min YJ, Jung SH, Park K, Mao M, Ahn MJ.
    Oncotarget; 2016 Feb 09; 7(6):6984-93. PubMed ID: 26755650
    [Abstract] [Full Text] [Related]

  • 18. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.
    Wang Z, Chen R, Wang S, Zhong J, Wu M, Zhao J, Duan J, Zhuo M, An T, Wang Y, Bai H, Wang J.
    PLoS One; 2014 Feb 09; 9(11):e110780. PubMed ID: 25405807
    [Abstract] [Full Text] [Related]

  • 19. The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
    Yoshimura A, Yamada T, Okura N, Takeda T, Furutani W, Kubota Y, Shiotsu S, Hiranuma O, Nishioka N, Chihara Y, Tamiya N, Kaneko Y, Uchino J, Takayama K.
    BMC Cancer; 2018 Dec 11; 18(1):1241. PubMed ID: 30537950
    [Abstract] [Full Text] [Related]

  • 20. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay.
    Wang MC, Wang CL, Chen TL, Chang JW, Lu JJ, Chang PY, Chiou CC.
    Clin Chem Lab Med; 2017 Oct 26; 55(12):1979-1986. PubMed ID: 28787267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.